

UCL School of Pharmacy ULLA – ExCo Parma 2019:

Research 2010

Michael Heinrich

Research Group

'Pharmacognosy and
Phytotherapy'

UCL School of Pharmacy,
Univ. London

29 - 39 Brunswick Sq.

London WC1N 1AX



London
02/03/2018

- Created in 1842 as the “School of Pharmacy of the Pharmaceutical Society of Great Britain”
- In 1926, it was incorporated into the University of London and was known as the School of Pharmacy, University of London (“The Square”)
- A very special School – not just in terms of achievements but also in terms of flagship status and professional outreach
- Since 2012 part of University College London
- Currently rated 7th in world for pharmacy and pharmacology (both QS and Shanghai)






Age-Related Medicines Development And Use



Drug Discovery And Therapeutic Target Identification



Translational Neuroscience



Fabrication And Synthetic Technologies For Advanced Drug Delivery



Medicines Use And Optimisation



Pharmacoepidemiology And Medication Safety

Age Related Medicines Development and Use

- Age appropriate formulation design (Orodispersibles, Multiparticulates, Taste masked formulations)
- Fixed dose combinations
- Age and gender related oral biopharmaceutics
- Preventive interventions (herbal substances)


Formulation Development & Biopharmaceutics

Formulation Testing

- In vitro sensory evaluation of formulations
- Brief Access Taste Aversion (BATA) model
- Human panel studies

- Pharmacometrics and paediatric PKPD modelling
- Dose rationale and clinical trial design for novel therapeutic interventions in special populations, paediatrics, geriatrics and rare diseases

Clinical Pharmacology & Translational Research




Projects (recently completed & ongoing)

- Assessing the taste of medicines with the rat “BATA” model; insight into the physiological aspect of taste
- Effective administration of multiparticulates to paediatric patients
- Advanced Therapeutics for Parkinson’s Disease Using Cell and Tissue Engineering and Biomaterials Technology
- Development of 3D printing technology for in-situ verification of dose
- Biopharmaceutics of excipients in paediatric medicines
-

Pharmacoepidemiology and medication safety


Informing and influencing policies to improve safety and benefit outcomes in the use of medicines

*through
record-linked
data research*



Research focus

- Cardiovascular disease, diabetes and mental health disorders and treatment, etc.
- Medication use incl. herbal medicines
- Medication errors and evaluation of pharmacy practice and technologies for safety improvement



Quality and safety of medicines, herbal medicines and related substances

Key c **Tweets** **Tweets & replies** **Media** **erns**

 UCL Fight The Fakes Retweeted



Oksana Pyzik @OksanaPyzikUCL · 19h

Great to meet with passionate professionals in #politics #healthcare & #tech dedicated to improving #healthsystems & #patientsafety at @EUParl_EN 🙌
Mike Isles ED of @ASOP_Europe keep fighting the good fight 🌟 @FightTheFakes @EU_Health @GiraudSylvain @School_Pharmacy @IAPOvoice



Vytenis Andriukaitis, José Inácio Faria, Aaron C and 7 others



Tomat



Potatoes



Rice




Simvastatin



Codeine

Medicines Use And Optimisation / Behavioural Medicine

Creating new knowledge to make healthcare more efficient and sustainable by understanding and addressing the psychosocial and behavioural factors explaining variation in response to treatment.







Research programme

-

Fabrication & Synthetic Technologies for Advanced Drug Delivery

Pharmaceutical technologies



Macro

3D printing
Inkjet printing
Crystal engineering
Hot melt extrusion
Tablets/minitables
Coating technologies
Liquid formulations

Micro

Spray drying
Emulsions
Suspensions

Nano

Electrospraying
Nano-in-micro formulations
Self-assembly
Electrospinning
Inorganic NPs

Molecular engineering


Novel polymers
Protein mimics/conjugates

Materials characterisation


Full gamut of techniques available. Particular expertise in thermal methods, synchrotron X-ray diffraction, electron and derivatised atomic force microscopies, hyphenated approaches, dissolution testing, IVIVC, protein binding, surface analysis

Fabrication & Synthetic Technologies for Advanced Drug Delivery

Routes of administration



Formulation development




Translational Neuroscience Cluster

Aims

- 1) Understand normal brain function,
- 2) Uncover the fundamental causes of neurological and psychiatric diseases
- 3) Identify novel therapeutic targets for their treatment.



Translational Neuroscience people



Stephanie Schorge - Gene therapy for the treatment of epilepsy

1% of population suffers from epilepsy, of which 25-30% have no effective treatment


Surgery for refractive epilepsy is dangerous and highly invasive

Gene therapy can be used even for non-genetic epileptic conditions – may be used to manipulate neuronal excitability


In the animal study, the rat seizures were effectively eradicated (cured?)

Stephanie has been awarded £1.9m by MRC to develop first human trial of this approach

Kätzel et al Chemical-genetic attenuation of focal neocortical seizures. Nat Commun. 2014 May 27;5:3847.



Drug discovery and target identification






Drug Discovery and Target Identification Therapeutic Focus

Antimicrobial targets e.g. malaria, antibiotic resistance, diabetes (natural products)

Cancer drug discovery e.g. kinesin drug targets, transcription factor targets including STAT3, and Nrf2

Targeted delivery of peptides and small molecules using nanoscale approaches



Mat Todd – open source drug discovery

Award winning pioneer of new approach to synthesis and discovery

Principle is that data and ideas are shared via a virtual community. New synthetic routes or new molecules can be developed via a coordinated shared lab book approach




Major initiatives in malaria, tuberculosis but as a model can be applied very widely indeed



NOVEMBER 30 2016


SAVE PRINT LICENSE ARTICLE

Sydney schoolboys take down Martin Shkreli, the 'most hated man in the world'

 Marcus Strom  




Dylan Siow-Lee holding about \$150,000 worth of Daraprim if sold in the US market. Photo: Nic Walker




Open Source
Malaria
Twitter: @O_S_M


MycetOS
Twitter @MycetOS
#OpenScience


Mycetoma
Neglected fungal/bacterial disease that leads to disability and stigma and has no effective treatment


PURPOSE
Develop new medicine to treat fungal mycetoma (eumycetoma) using an Open Pharma approach


CONCEPT



VIRTUAL COMMUNITY
Invite the scientific and global health community to contribute


OPEN ACCESS DATABASE
Drive lead optimization of compounds targeting *Mucorales* mycetomiasis

PROCESS


github
SHARE
DATA
PROJECT FILES


Twitter
COMMUNICATE
RESULTS
NEWS


reddit
FACILITATE
INTERACTIVE DISCUSSION

Free of intellectual property constraints
Launch participants:
University of Sydney - Mat Todd
Erasmus MC - Wendy van de Sande
Drugs for Neglected Diseases Initiative

- 1st Law: All data are open and all ideas are shared
- 2nd Law: Anyone can take part at any level
- 3rd Law: There will be no patents
- 4th Law: Suggestions are the best form of criticism
- 5th Law: Public discussion is much more valuable than private email
- 6th Law: An open project is bigger than, and is not owned by, any given lab




Age-Related Me
Development A



science

Thank you



Fabrication And Synthetic
Technologies For Advanced
Drug Delivery



Medicines Use And
Optimisation



Pharmacoepidemiology And
Medication Safety